Compare
Abbott Laboratories vs Tandem Diabetes Care (ABT vs TNDM)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Abbott Laboratories (ABT) returned -11.7% and Tandem Diabetes Care (TNDM) +15.3%; so far this year the figures are -12.3% and -23.1%.
Abbott Laboratories is the larger company by market value, about 161.3 times the size of Tandem Diabetes Care.
Revenue grew +10.0% at ABT and +6.8% at TNDM over the last year.
ABT yields 2.29%. TNDM pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABT | TNDM | |
|---|---|---|
| Price | $109.93 | $16.91 |
| 1-day | -3.23% | -6.00% |
| YTD | -12.26% | -23.07% |
| 1 year | -11.73% | +15.27% |
| 3 years | +15.70% | -4.73% |
| Market cap | $190.4B | $1.2B |
| P/E | 40.9 | — |
| P/S | 3.95 | 1.10 |
| P/B | 3.73 | 8.74 |
| Revenue growth | +10.00% | +6.80% |
| EPS growth | -66.20% | — |
| Gross margin % | 56.9 | 56.6 |
| Net margin % | 9.7 | -4.6 |
| ROE % | 9.2 | -36.4 |
| Debt / equity | 0.61 | 4.77 |
| FCF yield % | 3.5 | -3.1 |
| Dividend yield % | 2.29 | — |
| Beta | 0.06 | 1.11 |
| RSI (14) | 58.5 | 44.7 |
| Technical rating |